Glenmark Pharmaceuticals stock weighs Q1 growth against a Hold call

Published on 10/04/2026 at 14:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glenmark Pharmaceuticals stock was INR 2,331.00 on October 1, 2026, after a 0.16 percent decline. Q1 FY27 revenue rose 23.1 percent to INR 4,018.5 crore.

Glenmark, INE935A01035, Illustration mit AI erstellt.

Glenmark Pharmaceuticals stock, ISIN INE935A01035, stood at INR 2,331.00 on NSE India on October 1, 2026, after a 0.16 percent decline from the previous close. The market is weighing Q1 FY27 growth against a more cautious technical assessment published after the quarter.

Q1 growth remains substantial

According to DSIJ in its August 3, 2026 results update, Glenmark reported Q1 FY27 revenue of INR 4,018.5 crore, up 23.1 percent year over year. PAT rose 53.8 percent to INR 480 crore, while EBITDA increased 38.6 percent to INR 804.8 crore.

The operating picture improved as well. EBITDA margin reached 20 percent, an expansion of 220 basis points year over year, while North America revenue increased 41.1 percent to INR 1,097.4 crore and India formulations revenue grew 15.5 percent to INR 1,432.1 crore, according to DSIJ.

Hold call highlights pressure points

MarketsMojo reported on September 29, 2026, that its rating on Glenmark changed from Buy to Hold as of September 28. The assessment cited Q1 PAT of INR 482.92 crore, a 31.6 percent decline against the previous four-quarter average, and higher interest expenses of INR 54.00 crore.

The contrast is important for investors: the reported year-over-year comparison benefited from a weak prior-year base, while the sequential and average-quarter comparisons were less favorable. Glenmark also faces higher raw-material and freight costs, which Motilal Oswal included among the risks behind its estimates, according to DSIJ.

Stock stays below its yearly high

Glenmark's October 1 price of INR 2,331.00 was 8.14 percent below the 52-week high of INR 2,537.60 and above the 52-week low of INR 1,792.60. The stock's market capitalization was INR 657.8 billion, while volume reached 972,519 shares on the same session.

The Economic Times lists a mean Buy recommendation from 8 analysts, with 3 Strong Buy, 3 Buy and 2 Hold ratings, according to its October 1, 2026 market page. Its Q1 table shows revenue of INR 4,084.25 crore and PAT of INR 482.92 crore for June 2026, alongside a net profit margin of 11.82 percent.

Glenmark Pharmaceuticals stock price

Glenmark Pharmaceuticals stock was last at INR 2,331.00 on NSE India on October 1, 2026, with the session change at minus 0.16 percent. The quotation remains within a 52-week range of INR 1,792.60 to INR 2,537.60.